GlobalData on MSN11h
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Investor's Business Daily on MSN1h
BioNTech Stock Got A IBD RS Rating LiftHow Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
BioNTech, the German developer of a widely used mRNA vaccine for the coronavirus, agreed to pay US$800 million (HK$6.24 ...
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a ...
John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...
Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a ...
Analysten sehen Milliardenpotenzial, rasant steigende Umsätze und ein günstiges KGV. Auch die BioNTech-Aktie profitiert von einer Hochstufung durch renommierte Analysten. Das Kursziel wird deutlich ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
Frankfurt/Main (dpa) - Mainz bleibt einer Studie zufolge auch im dritten Jahr hintereinander die dynamischste Großstadt in ...
MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 10:30 a.m. Eastern ...
Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback